Kevin J. Anstrom

31.2k total citations · 9 hit papers
328 papers, 15.5k citations indexed

About

Kevin J. Anstrom is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Kevin J. Anstrom has authored 328 papers receiving a total of 15.5k indexed citations (citations by other indexed papers that have themselves been cited), including 201 papers in Cardiology and Cardiovascular Medicine, 70 papers in Pulmonary and Respiratory Medicine and 64 papers in Surgery. Recurrent topics in Kevin J. Anstrom's work include Heart Failure Treatment and Management (101 papers), Cardiovascular Function and Risk Factors (60 papers) and Cardiac pacing and defibrillation studies (43 papers). Kevin J. Anstrom is often cited by papers focused on Heart Failure Treatment and Management (101 papers), Cardiovascular Function and Risk Factors (60 papers) and Cardiac pacing and defibrillation studies (43 papers). Kevin J. Anstrom collaborates with scholars based in United States, Canada and United Kingdom. Kevin J. Anstrom's co-authors include Daniel B. Mark, Eric L. Eisenstein, Eric D. Peterson, Adrian F. Hernandez, G. Michael Felker, Judith M. Kramer, Steven E. McNulty, Kevin A. Schulman, Christopher M. O’Connor and Margaret M. Redfield and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Kevin J. Anstrom

314 papers receiving 15.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

2020 781 citations Kevin J. Anstrom, Justin A. Ezekowitz et al. profile →
Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation

2006 623 citations Eric L. Eisenstein, Kevin J. Anstrom et al. profile →
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction

2016 475 citations Kenneth B. Margulies, Adrian F. Hernandez et al. profile →
Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation

2019 386 citations Daniel B. Mark, Kevin J. Anstrom et al. profile →
Palliative Care in Heart Failure

2017 381 citations Robert J. Mentz, Kevin J. Anstrom et al. Journal of the American College of Cardiology profile →
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction

2015 370 citations Kevin J. Anstrom, Horng H. Chen et al. profile →
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency

2017 323 citations Adrian F. Hernandez, G. Michael Felker et al. profile →
Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction

2017 321 citations G. Michael Felker, Kevin J. Anstrom et al. profile →
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction

2020 184 citations Paul W. Armstrong, Carolyn S.P. Lam et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kevin J. Anstrom United States	63	9.4k	3.6k	3.6k	1.3k	1.3k	328	15.5k
Robert N. Foley United States	70	5.4k 0.6×	3.7k 1.0×	4.1k 1.1×	1.4k 1.0×	1.0k 0.8×	199	19.6k
Allan J. Collins United States	80	4.9k 0.5×	3.7k 1.0×	3.8k 1.1×	1.6k 1.2×	2.0k 1.5×	275	22.6k
Chi‐yuan Hsu United States	57	5.8k 0.6×	3.5k 1.0×	3.9k 1.1×	2.5k 1.9×	2.3k 1.7×	202	23.2k
Larry A. Allen United States	62	11.1k 1.2×	2.4k 0.7×	1.6k 0.5×	1.1k 0.8×	1.9k 1.5×	345	16.8k
Sripal Bangalore United States	69	11.7k 1.2×	5.7k 1.6×	2.3k 0.6×	2.4k 1.9×	1.3k 1.0×	479	18.4k
Mark J. Sarnak United States	81	9.0k 1.0×	3.9k 1.1×	4.2k 1.1×	2.7k 2.0×	3.0k 2.3×	288	27.9k
Michael E. Farkouh United States	60	6.8k 0.7×	4.9k 1.3×	2.4k 0.7×	2.0k 1.5×	1.5k 1.2×	342	15.2k
Mark H. Drazner United States	57	14.4k 1.5×	3.3k 0.9×	2.3k 0.6×	1.4k 1.1×	1.5k 1.2×	236	18.9k
Mariell Jessup United States	59	19.3k 2.1×	5.6k 1.5×	3.0k 0.8×	1.4k 1.1×	1.7k 1.3×	194	25.6k
Brian Claggett United States	74	12.4k 1.3×	2.3k 0.6×	3.1k 0.9×	4.0k 3.0×	1.4k 1.1×	550	19.4k

Countries citing papers authored by Kevin J. Anstrom

Since Specialization

Citations

This map shows the geographic impact of Kevin J. Anstrom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin J. Anstrom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin J. Anstrom more than expected).

Fields of papers citing papers by Kevin J. Anstrom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin J. Anstrom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin J. Anstrom. The network helps show where Kevin J. Anstrom may publish in the future.

Co-authorship network of co-authors of Kevin J. Anstrom

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin J. Anstrom. A scholar is included among the top collaborators of Kevin J. Anstrom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin J. Anstrom. Kevin J. Anstrom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mark, Daniel B., Michael G. Nanna, Michelle D. Kelsey, et al.. (2025). Quality of Life Outcomes With a Risk-Based Precision Testing Strategy Versus Usual Testing in Stable Patients With Suspected Coronary Disease: Results From the PRECISE Randomized Trial. Circulation Cardiovascular Quality and Outcomes. 18(2). e011414–e011414.

O’Connor, Christopher M., Devan V. Mehrotra, Ciaran J. McMullan, et al.. (2025). Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification. Journal of Cardiac Failure.

Greene, Stephen J., Robert M. Clare, Daniel Wojdyla, et al.. (2024). Diuretic Dosing and Outcomes with Torsemide and Furosemide Following Hospitalization for Heart Failure: The TRANSFORM-HF Trial. European Journal of Heart Failure. 27(2). 317–324. 4 indexed citations

Kreuziger, Lisa Baumann, Raj S. Kasthuri, Lana Wahid, et al.. (2024). High-risk subgroups were not identified to benefit from thromboprophylaxis after hospitalization for COVID-19. Research and Practice in Thrombosis and Haemostasis. 8(4). 102417–102417.

Hong, Hwanhee, Kevin J. Anstrom, Susan Halabi, et al.. (2023). Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials. BMJ Open. 13(6). e065305–e065305. 4 indexed citations

Greene, Stephen J., Justin A. Ezekowitz, Kevin J. Anstrom, et al.. (2022). Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Journal of Cardiac Failure. 28(7). 1063–1077. 33 indexed citations

Eisenstein, Eric L., Shelly Sapp, Tina Harding, et al.. (2022). Ascertaining Death Events in a Pragmatic Clinical Trial: Insights From the TRANSFORM-HF Trial. Journal of Cardiac Failure. 28(10). 1563–1567. 3 indexed citations

Poole, Jeanne E., Brian Olshansky, Daniel B. Mark, et al.. (2020). Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. Journal of the American College of Cardiology. 76(4). 405–415. 51 indexed citations

Butler, Javed, Stephen J. Greene, Svati H. Shah, et al.. (2019). Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. Journal of Cardiac Failure. 26(5). 371–380. 23 indexed citations

10.

O’Brien, Emily C., Michael T. Durheim, Victoria Gamerman, et al.. (2016). Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry. BMJ Open Respiratory Research. 3(1). e000108–e000108. 38 indexed citations

11.

Salisbury, Margaret L., David A. Lynch, Edwin J.R. van Beek, et al.. (2016). Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes. American Journal of Respiratory and Critical Care Medicine. 195(7). 921–929. 96 indexed citations

12.

Kaul, Padma, E. Magnus Ohman, J. David Knight, et al.. (2016). Health-related quality of life outcomes with prasugrel among medically managed non–ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. American Heart Journal. 178. 55–64. 3 indexed citations

13.

Alexander, Karen P., Giora Weisz, Kristi Prather, et al.. (2015). Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization. Circulation. 133(1). 39–47. 37 indexed citations

14.

Wang, Tracy Y., Timothy D. Henry, Mark B. Effron, et al.. (2015). Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. Circulation Cardiovascular Interventions. 8(6). e001712–e001712. 13 indexed citations

15.

Oldham, Justin M., Shwu‐Fan Ma, Fernando J. Martínez, et al.. (2015). TOLLIP , MUC5B , and the Response to N -Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 192(12). 1475–1482. 218 indexed citations

16.

Grodin, Justin L., Susanna R. Stevens, Lisa de las Fuentes, et al.. (2015). Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. Journal of Cardiac Failure. 22(1). 26–32. 41 indexed citations

17.

Raghu, Ganesh, Harold R. Collard, Kevin J. Anstrom, et al.. (2012). Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials. American Journal of Respiratory and Critical Care Medicine. 185(10). 1044–1048. 154 indexed citations

18.

Noth, Imre, Kevin J. Anstrom, Sara B. Calvert, et al.. (2012). A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 186(1). 88–95. 317 indexed citations

19.

Bagai, Akshay, Eric D. Peterson, Emily Honeycutt, et al.. (2012). Abstract 15573: In-Hospital Switching of ADP Receptor Inhibitors in Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the TRANSLATE-ACS Study. Circulation. 126. 4 indexed citations

20.

Reed, Shelby D., Kevin J. Anstrom, Ameet Bakhai, et al.. (2005). Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. American Heart Journal. 149(3). 434–443. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact